These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 28593386)

  • 1. Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma-a preliminary analysis.
    Klein Nulent TJW; van Es RJJ; Krijger GC; de Bree R; Willems SM; de Keizer B
    Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1614-1621. PubMed ID: 28593386
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    van Boxtel W; Lütje S; van Engen-van Grunsven ICH; Verhaegh GW; Schalken JA; Jonker MA; Nagarajah J; Gotthardt M; van Herpen CML
    Theranostics; 2020; 10(5):2273-2283. PubMed ID: 32089741
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostate-specific membrane antigen (PSMA) expression in adenoid cystic carcinoma of the head and neck.
    Klein Nulent TJW; Valstar MH; Smit LA; Smeele LE; Zuithoff NPA; de Keizer B; de Bree R; van Es RJJ; Willems SM
    BMC Cancer; 2020 Jun; 20(1):519. PubMed ID: 32503460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lutetium-177-PSMA therapy for recurrent/metastatic salivary gland cancer: a prospective pilot study.
    van Ruitenbeek NJ; Uijen MJM; Driessen CML; Peters SMB; Privé BM; van Engen-van Grunsven ACH; Konijnenberg MW; Gotthardt M; Nagarajah J; van Herpen CML
    Theranostics; 2024; 14(14):5388-5399. PubMed ID: 39310108
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of 68Ga-PSMA-HBED-CC and 18F-FDG PET/CT in the Evaluation of Adenoid Cystic Carcinoma-A Prospective Study.
    Shamim SA; Kumar N; Arora G; Kumar D; Pathak A; Thakkar A; Sikka K; Singh CA; Kakkar A; Bhalla AS
    Clin Nucl Med; 2023 Nov; 48(11):e509-e515. PubMed ID: 37812520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there a nonnegligible effect of maximum standardized uptake value in the staging and management of prostate cancer with 68Ga-prostate-specific membrane antigen positron emission tomography/computerized tomography imaging? A single-center experience.
    Ekmekcioglu O; Yavuzsan AH; Arican P; Kirecci SL
    J Cancer Res Ther; 2021; 17(6):1351-1357. PubMed ID: 34916365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of
    Siva S; Callahan J; Pryor D; Martin J; Lawrentschuk N; Hofman MS
    J Med Imaging Radiat Oncol; 2017 Jun; 61(3):372-378. PubMed ID: 28116853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlations of the
    Karyagar SS; Karyagar S; Guven O
    Hell J Nucl Med; 2020; 23(2):120-124. PubMed ID: 32716402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiologic distribution of PSMA-ligand in salivary glands and seromucous glands of the head and neck on PET/CT.
    Klein Nulent TJW; Valstar MH; de Keizer B; Willems SM; Smit LA; Al-Mamgani A; Smeele LE; van Es RJJ; de Bree R; Vogel WV
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May; 125(5):478-486. PubMed ID: 29523427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
    Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
    Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of
    Hofman MS; Eu P; Jackson P; Hong E; Binns D; Iravani A; Murphy D; Mitchell C; Siva S; Hicks RJ; Young JD; Blower PJ; Mullen GE
    J Nucl Med; 2018 Apr; 59(4):625-631. PubMed ID: 28986512
    [No Abstract]   [Full Text] [Related]  

  • 13. Prediction of distant metastasis and survival in adenoid cystic carcinoma using quantitative
    Lim WS; Oh JS; Roh JL; Kim JS; Kim SJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2018 Feb; 77():98-104. PubMed ID: 29362133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with
    Ferraro DA; Rüschoff JH; Muehlematter UJ; Kranzbühler B; Müller J; Messerli M; Husmann L; Hermanns T; Eberli D; Rupp NJ; Burger IA
    Theranostics; 2020; 10(14):6082-6094. PubMed ID: 32483440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of peptide-based imaging agents [
    Zhang-Yin J; Provost C; Cancel-Tassin G; Rusu T; Penent M; Radulescu C; Comperat E; Cussenot O; Montravers F; Renard-Penna R; Talbot JN; Prignon A
    Nucl Med Biol; 2020; 84-85():88-95. PubMed ID: 32251995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First Clinicopathologic Evidence of a Non-PSMA-Related Uptake Mechanism for
    Rupp NJ; Umbricht CA; Pizzuto DA; Lenggenhager D; Töpfer A; Müller J; Muehlematter UJ; Ferraro DA; Messerli M; Morand GB; Huber GF; Eberli D; Schibli R; Müller C; Burger IA
    J Nucl Med; 2019 Sep; 60(9):1270-1276. PubMed ID: 30737300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Prostate-Specific Membrane Antigen PET/CT and Contrast-Enhanced Magnetic Resonance Imaging in Follow-up Assessment of Juvenile Nasal Angiofibroma-A Novel Pilot Study.
    Thakar A; Sakthivel P; Arunraj ST; Bhalla AS; Kakkar A; Kumar R; Kumar R
    Clin Nucl Med; 2020 Dec; 45(12):e498-e504. PubMed ID: 33065615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients.
    Plouznikoff N; Artigas C; Sideris S; Martinez Chanza N; Gil T; Peltier A; Flamen P
    Ann Nucl Med; 2019 Dec; 33(12):945-954. PubMed ID: 31587172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.
    Xiang M; Ma TM; Savjani R; Pollom EL; Karnes RJ; Grogan T; Wong JK; Motterle G; Tosoian JJ; Trock BJ; Klein EA; Stish BJ; Dess RT; Spratt DE; Pilar A; Reddy C; Levin-Epstein R; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Huland H; Tran PT; Martin S; Martinez-Monge R; Krauss DJ; Abu-Isa EI; Alam R; Schwen Z; Pisansky TM; Choo CR; Song DY; Greco S; Deville C; McNutt T; DeWeese TL; Ross AE; Ciezki JP; Boutros PC; Nickols NG; Bhat P; Shabsovich D; Juarez JE; Chong N; Kupelian PA; Rettig MB; Zaorsky NG; Berlin A; Tward JD; Davis BJ; Reiter RE; Steinberg ML; Elashoff D; Horwitz EM; Tendulkar RD; Tilki D; Czernin J; Gafita A; Romero T; Calais J; Kishan AU
    JAMA Netw Open; 2021 Dec; 4(12):e2138550. PubMed ID: 34902034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.